Advanced Maternal Age:
What Being 35+ Actually Means

What Advanced Maternal Age Actually Means

Advanced maternal age (AMA) is defined as being 35 years or older at the expected time of delivery. That’s it. It is a statistical category, not a diagnosis. It does not mean your pregnancy is high-risk. It does not mean something is wrong. It means you fall into a demographic group where certain risks begin to increase — gradually, not suddenly.

The term “geriatric pregnancy,” while still used informally, has been largely replaced in clinical settings by “advanced maternal age” or simply “AMA.” Neither term is meant to be pejorative — they exist because obstetric data needs categorical thresholds for screening recommendations and risk stratification.

Why 35? The Historical Context

The age-35 threshold became standard in the 1970s and 1980s, when amniocentesis was the primary method for detecting chromosomal abnormalities. At that time, the risk of trisomy 21 (Down syndrome) at age 35 — approximately 1 in 350 — roughly equaled the estimated risk of pregnancy loss from the amniocentesis procedure itself. It was a risk-balancing calculation, not a biological cliff.

Modern screening has fundamentally changed this equation. Cell-free DNA testing (NIPT) is non-invasive and has dramatically higher sensitivity than the age-based cutoffs used decades ago. The amniocentesis procedure-related loss rate is now estimated at 1 in 900 or lower at experienced centers Akolekar et al., 2015. ACOG now recommends offering screening to all patients regardless of age, which means the 35-year threshold is less clinically relevant than it once was — but the term persists.

For a comprehensive overview of how AMA fits into the broader context of pregnancy risk assessment, see our High-Risk Pregnancy Guide.

What the Statistics Show — and What They Don’t

The risk numbers associated with AMA are real, but they are frequently presented without context. Understanding both the relative increase and the absolute numbers is essential.

Chromosomal Abnormalities

The risk of trisomy 21 (Down syndrome) increases with maternal age, but the absolute numbers are often smaller than patients expect:

• Age 25: approximately 1 in 1,250
• Age 30: approximately 1 in 950
• Age 35: approximately 1 in 350
• Age 38: approximately 1 in 190
• Age 40: approximately 1 in 100
• Age 42: approximately 1 in 55

These numbers mean that at age 35, you have a 99.7% chance of NOT having a baby with trisomy 21. At age 40, it is still a 99% chance. The risk increases are real and warrant screening, but they do not define your pregnancy.

Gestational Diabetes and Preeclampsia

Women over 35 have a moderately increased risk of gestational diabetes mellitus (GDM), with studies showing approximately a 1.5–2x relative increase compared to women under 30 Lean et al., 2017. Similarly, preeclampsia risk increases with maternal age, with women over 40 having roughly twice the risk of women in their 20s.

However, both conditions are modifiable with early detection and management. GDM is screened for universally between 24 and 28 weeks (and earlier in high-risk patients). Preeclampsia risk can be reduced with low-dose aspirin prophylaxis starting at 12–16 weeks in patients with identified risk factors ACOG, 2020.

What the Statistics Do NOT Show

Risk tables rarely mention that the vast majority of AMA pregnancies are uncomplicated. A 37-year-old with no prior medical conditions, a healthy BMI, good blood pressure, and appropriate prenatal care has an excellent chance of an entirely normal pregnancy and delivery. Age is one risk factor among many — it is not destiny.

ACOG Screening Recommendations

One of the most significant changes in prenatal care in the past decade has been the shift away from age-based screening toward universal screening offered to all patients. ACOG Practice Bulletin #226 (2020) is clear: aneuploidy screening and diagnostic testing should be discussed with and offered to all pregnant patients, regardless of maternal age or risk factors.

Cell-Free DNA Screening (NIPT)

Non-invasive prenatal testing (NIPT) analyzes fragments of placental DNA circulating in the mother’s blood. It can be performed as early as 10 weeks and has a detection rate for trisomy 21 of greater than 99% with a false-positive rate under 0.1% Gil et al., 2017. For patients 35 and older, NIPT is commonly offered as a first-line screening option.

It is important to understand that NIPT is a screening test, not a diagnostic test. A positive NIPT result indicates increased risk and should be followed by diagnostic testing (CVS or amniocentesis) for confirmation before any clinical decisions are made.

Diagnostic Testing

For patients who want definitive answers — or who receive a positive screening result — two diagnostic options are available:

• Chorionic villus sampling (CVS): Performed at 10–13 weeks. Samples placental tissue for chromosomal analysis. Results typically within 7–14 days.
• Amniocentesis: Performed at 15–20 weeks. Samples amniotic fluid. Considered the gold standard for chromosomal diagnosis. Procedure-related loss rate estimated at approximately 1 in 900.

ACOG no longer recommends using age alone to determine who should be offered diagnostic testing. Any patient may go directly to diagnostic testing if they choose, without screening first. The decision should be based on patient values and informed consent, not on a rigid algorithm.

Enhanced Monitoring for AMA

Even when an AMA pregnancy is progressing normally, most providers will implement enhanced monitoring in the second half of pregnancy. This is not because something is wrong — it is because earlier detection of any developing complication leads to better outcomes.

Third-Trimester Monitoring

• More frequent prenatal visits: Beginning around 32–34 weeks, visits may increase from monthly to every 2 weeks, then weekly from 36 weeks onward. Blood pressure and urine protein are assessed at each visit to screen for preeclampsia.
• Serial growth ultrasounds: If there is concern about fetal growth restriction or macrosomia (large baby, often associated with GDM), serial ultrasounds every 3–4 weeks may be ordered to track fetal growth velocity.
• Antenatal testing (non-stress tests): NSTs may be initiated at 36 weeks (some providers begin at 37–39 weeks depending on individual risk profile). An NST monitors fetal heart rate patterns for 20–40 minutes and is a simple, non-invasive assessment of fetal wellbeing.
• Amniotic fluid assessment: Biophysical profiles (BPP) or amniotic fluid index (AFI) checks may be added, particularly in the final weeks of pregnancy.

Delivery Timing

For uncomplicated AMA pregnancies, ACOG and the ARRIVE trial data support a discussion about delivery timing. The current evidence suggests:

• Age 35–39 with no complications: Delivery by 39 weeks 0 days to 39 weeks 6 days is reasonable, with individualized discussion.
• Age 40 and older with no complications: Delivery at 39 weeks 0 days to 39 weeks 6 days is generally recommended due to the slightly increased stillbirth risk in late-term pregnancies at this age.
• AMA with additional risk factors: Delivery timing may be earlier depending on the specific complication (GDM, preeclampsia, growth restriction).

This does not mean induction is mandatory. It means the conversation about timing happens earlier and is guided by data specific to your clinical picture. At Broad Medical Group, Dr. Broad discusses delivery planning individually, typically beginning around 36–37 weeks.

What 35+ Does NOT Mean

Misinformation and outdated assumptions about AMA are widespread. Here is what advanced maternal age does not mean:

It Does Not Mandate a C-Section

Advanced maternal age alone is not an indication for cesarean delivery. While C-section rates are statistically higher in women over 35, this reflects a combination of factors: higher induction rates, increased prevalence of conditions like preeclampsia and gestational diabetes, and sometimes provider practice patterns. Many women over 35 — and over 40 — have successful vaginal deliveries. The mode of delivery should be determined by obstetric indications, not age.

It Does Not Mean Automatic “High-Risk” Classification

AMA is a risk factor, not a diagnosis. A 36-year-old with no medical history, normal blood pressure, normal screening results, and a normally growing fetus is not in the same category as a patient with preeclampsia or fetal growth restriction. The label “high-risk” should be based on what is actually happening in the pregnancy, not solely on maternal age. Enhanced monitoring is warranted; panic is not.

It Does Not Mean IVF Is Required

Fertility does decline with age, but many women over 35 conceive spontaneously. AMA does not mean you need assisted reproduction. If you have been trying for 6 months without success (the recommended threshold for evaluation in women 35+, versus 12 months for younger women), a fertility evaluation is appropriate. But plenty of AMA pregnancies begin without any medical intervention.

It Does Not Mean You Cannot Have a Healthy Pregnancy

This is the most important point. The majority of women over 35 have healthy pregnancies and healthy babies. Enhanced screening exists to catch the uncommon complications early — not because those complications are expected. With appropriate prenatal care, evidence-based monitoring, and an informed, engaged provider, age 35+ is a starting point for a conversation, not a sentence.